BioSpace News Archive

Business

Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021

Dynavax Technologies Corporation will report third quarter 2021 financial results on Thursday, November 4, 2021, after the U.S. financial markets close.

October 21, 2021
·
1 min read
Pharm Country

New Study Supports Coffee and Caffeine Can Reduce Kidney Stones Risk

A new study using genetic data of hundreds of thousands of people suggests that daily coffee and caffeine consumption can prevent kidney stones.

October 21, 2021
·
3 min read
Pharm Country

Harmony Biosciences to be Added to the S&P SmallCap 600® Index

Harmony Biosciences Holdings, Inc. today announced that it will be added to the S&P SmallCap 600 ® Index, effective prior to the open of trading on Friday, October 22, 2021.

October 21, 2021
·
1 min read
Biotech Bay

Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit

Graphite Bio, Inc. announced today that members of the management team will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Thursday, Oct. 28, 2021, at 4:30 p.m. ET.

October 21, 2021
·
1 min read
Drug Development

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

Teva Pharmaceuticals today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets.

October 21, 2021
·
13 min read
Business

Arcturus Therapeutics Announces Leadership Appointments

Arcturus Therapeutics Holdings Inc. announced the appointments of Dr. Nirdosh Jagota as the Chief Regulatory Officer and Dr. Dushyant B. Varshney as the Chief Technology Officer.

October 21, 2021
·
7 min read
Pharm Country

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Silence Therapeutics plc announces it is hosting its R&D Day in New York City today.

October 21, 2021
·
15 min read
Business

Antares Pharma to Report Third Quarter 2021 Financial and Operating Results

Antares Pharma, Inc. today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens.

October 21, 2021
·
5 min read
Drug Development

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo.

October 21, 2021
·
8 min read
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

October 21, 2021
·
4 min read